A randomised, controlled trial of exit site application of MedihoneyTM Antibacterial Wound Gel for the prevention of catheter-associated infections in peritoneal dialysis patients, The HONEYPOT Study
Phase 3
Completed
- Conditions
- Peritoneal dialysisChronic renal failureRenal and Urogenital - Kidney diseaseAlternative and Complementary Medicine - Other alternative and complementary medicine
- Registration Number
- ACTRN12607000537459
- Lead Sponsor
- Australasian Kidney Trials Network
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 371
Inclusion Criteria
Receiving peritoneal dialysis.
Able to give informed consent.
Exclusion Criteria
Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study. Recent (within 1 month) exit site infection, peritonitis, or tunnel infection. Known hypersensitivity to, or intolerance of, honey or mupirocin. On long term antibiotics. Nasal carriage of mupirocin resistant Staphylococcus aureus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to first episode of exit site infection, tunnel infection or peritonitis (whichever comes first)[Time from study entry]
- Secondary Outcome Measures
Name Time Method Costs[Assessed throughout the study period];Time to first episode of peritonitis[Time from study entry];Time to first tunnel infection[Time from study entry];Time to first exit site infection[Time from study entry];Time to infection-associated catheter removal[Time from study entry];Catheter-associated infection rates[Assessed throughout the study period];Occurrence of mupirocin-resistant microbial isolates[Assessed throughout the study period];Incidence of adverse reactions[Assessed throughout the study period]